Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 47,900 shares, an increase of 26.4% from the May 15th total of 37,900 shares. Based on an average daily volume of 34,300 shares, the days-to-cover ratio is currently 1.4 days. Currently, 2.1% of the shares of the company are sold short.
Biomerica Stock Performance
Shares of BMRA opened at $3.28 on Thursday. Biomerica has a 1 year low of $1.93 and a 1 year high of $10.16. The company has a market cap of $8.36 million, a price-to-earnings ratio of -1.41 and a beta of 0.34. The firm has a fifty day moving average of $3.52 and a 200-day moving average of $4.02.
Biomerica (NASDAQ:BMRA – Get Free Report) last announced its quarterly earnings results on Monday, April 14th. The company reported ($0.48) earnings per share (EPS) for the quarter. The firm had revenue of $1.12 million for the quarter. Biomerica had a negative net margin of 85.42% and a negative return on equity of 85.90%.
Institutional Investors Weigh In On Biomerica
About Biomerica
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Featured Articles
- Five stocks we like better than Biomerica
- Which Wall Street Analysts are the Most Accurate?
- Cantor Boosts Rocket Lab Target to Street-High $35
- Best Stocks Under $10.00
- Why Amazon Could Be About To Breakout To $250
- A Deeper Look at Bid-Ask Spreads
- Chime’s Smart IPO: Half the Valuation, Double the Strength
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.